Clobazam meets Phase III endpoint

H. Lundbeck A/S (CSE:LUN) said clobazam met the primary endpoint in a Phase III trial to treat Lennox-Gastaut syndrome (LGS). The 1,5-benzodiazepine compound significantly reduced the average number o...